Conitec has Public Call No. 27 open to hear SUS users, as well as family members, caregivers, and guardians who have experience with the drug under review: Deferiprone.
The objective is to collect experiences from adult patients with sickle cell disease.
The participation of volunteers, who are increasingly present in regulatory incorporation processes, is an opportunity for SUS users to participate during the Conitec Meeting and share (successful) experiences in dealing with various health conditions. It is also an opportunity to add real-life resources to the agency's assessment.
Publicize and contribute by May 20: https://www.gov.br/participamaisbrasil/chamada-publica-27-2024-deferiprona
